论文部分内容阅读
目的对比西利宾胺与其他肺结核药物治疗继发型肺结核合并肝损害患者的临床疗效与安全性。方法选取2010年4月到2011年4月期间住院治疗的90例初治继发型肺结核合并肝损害患者作为研究对象。随机分为实验组与对照组,各45例。两组均按照常规抗结核化疗方案[2HRZS(E)/4HR]进行治疗,实验组在此基础上给予西利宾胺,对照组在此基础上给予肌苷。观察两组的临床疗效。结果实验组的总有效率为88.9%,对照组的总有效率为60.0%,两组比较差异有统计学意义(χ2=9.870,P<0.01)。实验组的肝功能总恢复率78.8%,明显高于对照组的62.2%,差异有统计学意义(χ2=4.141,P<0.05)。实验组治疗耐受率[1-(抗结核化疗中断率+化疗方案调整率]高于对照组(93.4%vs 75.5%,χ2=5.408,P<0.05)。结论西利宾胺治疗继发型肺结核合并肝损害患者临床疗效显著,安全性较高。
Objective To compare the clinical efficacy and safety of carprostamine with other pulmonary tuberculosis drugs in the treatment of secondary pulmonary tuberculosis complicated with liver damage. Methods 90 patients with newly diagnosed secondary pulmonary tuberculosis complicated with liver damage hospitalized from April 2010 to April 2011 were selected as the research object. Randomly divided into experimental group and control group, 45 cases each. Both groups were treated according to the conventional anti-tuberculosis chemotherapy regimen [2HRZS (E) / 4HR]. In the experimental group, ceibalierine was given on the basis of this and the control group was given inosine. The clinical efficacy of the two groups was observed. Results The total effective rate was 88.9% in the experimental group and 60.0% in the control group. The difference between the two groups was statistically significant (χ2 = 9.870, P <0.01). The total recovery rate of hepatic function in the experimental group was 78.8%, which was significantly higher than that in the control group (62.2%, χ2 = 4.141, P <0.05). The tolerability of treatment group [1- (anti-tuberculosis chemotherapy discontinuation rate and chemotherapy regimen adjustment rate) was higher than that of the control group (93.4% vs 75.5%, χ2 = 5.408, P0.05) .Conclusion Siliverbin treatment of secondary pulmonary tuberculosis Clinical efficacy of liver damage in patients with significant, higher safety.